Uncategorized

Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share positive topline results from the Phase 3 PHOENYCS GO study evaluating the investigational therapy dapirolizumab pegol in people living with moderate-to-severe systemic lupus. Results of the Phase 3 PHOENYCS GO study were reported by study sponsors UCB and Biogen. The … Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

Statement in Response to Recent Lupus Science and Medicine Publication

|

A study recently published in Lupus Science and Medicine showed that krill oil concentrate helped to increase Omega-3 deficiency in people living with lupus. Secondary findings on a small subset of people with more severe lupus in the ORKIDS study suggest that krill oil concentrate may impact disease activity, but further study is warranted. Lupus … Statement in Response to Recent Lupus Science and Medicine Publication

On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

|

As part of Lupus Awareness Month, May 1 has been declared “Lupus Call to Action Day” by the National Minority Health Association (NMHA) and members of the lupus community. Kicking off at NYU Langone Health in New York City, the high-profile platform is designed to drive awareness and enact change to improve equity and inclusion … On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

Lupus Peer-to-Peer Early Education Program Expands

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support to people with … Lupus Peer-to-Peer Early Education Program Expands

Summary Highlights of Important Research Presented at ACR Convergence 2023

|

At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is Showing Great … Summary Highlights of Important Research Presented at ACR Convergence 2023

Positive One-Year Results of PALS Program Published in Prestigious Rheumatology Journal

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share that the successful results of the Patient Advocates for Lupus Studies (PALS) pilot study were recently published in ACR Open Rheumatology , the official open-access journal of the American College of Rheumatology. The PALS (Patient Advocates for Lupus Studies) Program was … Positive One-Year Results of PALS Program Published in Prestigious Rheumatology Journal

Lupus Therapeutics PALS Program Expansion

|

Call for Individuals to Serve as a Trained Peer Educator Lupus Therapeutics, the clinical affiliate of Lupus Research Alliance, is pleased to announce the expansion of the highly successful Patient Advocates for Lupus Studies (PALS) pilot program with an exciting request for people who have clinical trial experience as well as a lupus diagnosis to … Lupus Therapeutics PALS Program Expansion

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

|

The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common lupus complication causing … Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

|

We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food and Drug Administration’s … NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

|

We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England Journal of Medicine showing that the investigational therapy litifilimab (BIIB059) lessened skin disease activity in cutaneous lupus erythematosus. There is a great unmet need for people with cutaneous lupus, a type of lupus with few treatment options that … New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

|

The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates the levels of … Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

Ask About Clinical Trial Opportunities

|

Advocating for your own best care includes raising the possibility of joining a clinical trial with your healthcare provider.  Here’s more on how: It is important for individuals who are considering participation in a trial to understand what will be involved.  The National Institutes of Health (NIH) asking the healthcare team overseeing the study about … Ask About Clinical Trial Opportunities